1 Supplementary information

1.1 Physiology



Supplementary Figure 1: (a,b) Scatter plots showing real blood gas results from critically ill patients. S/F is plotted against a gold standard, P/F. Points are coloured according the S_aO_2 as shown in the colour scale. (a) including all values with no maximum S_aO_2 . Linear regression lines are shown for S/F against P/F in using different maxima for S_aO_2 ; patients breathing air $(F_IO_2=21\%)$ were included in all regression analyses regardless of S_aO_2 . (b) shows only values meeting the criteria for S/F_{94} : $S_aO_2 < 94\%$ or $F_IO_2 = 21\%$ (c) Optimisation of cut-off value for S_aO_2 using change in correlation coefficient (Spearman r) as the threshold for inclusion is lowered from $S_aO_2 < 100\%$ to $S_aO_2 < 80\%$.



Supplementary Figure 2: Predictive validity (ability to predict a future P_aO_2 after a change in F_IO_2 ; absolute error in kPa) of Alveolar- arterial (A-a), P/F ratio (P/F), effective shunt fraction (ES), and S/F ratio (S/F), compared to a baseline (the minimum achievable error, measured as the change in P_aO_2 between pairs of arterial blood gas measurements meeting the other selection criteria, with no change in F_IO_2). Lower values indicate superior validity. All values are included in (a); in (b) only values in which $S_aO_2 < 0.94$ in the first measurement.

1.2 Evaluation in ISARIC data

1.2.1 Respiratory Rate

There is large variation in respiratory rate, which is independent of S/F_{94} . As expected, there is a tendency of higher respiratory rates for patients with a lower S/F_{94} (Supplementary Figure 3)



Supplementary Figure 3: Relationship between respiratory rate and the S/F_{94} in 49,727 patients meeting inclusion criteria (age 20-75; oxygen therapy in first 3 days of admission).

1.2.2 Association between mortality at day 28 and S/F_{94}

The relationship between S/F_{94} on day 0 and mortality in the multivariable model appears counter-intuitive (Supplementary Figure 4a). A univariable regression model with mortality on day 28 as the outcome variable and S/F_{94} on day 0 as the predictor, shows a relationship as expected: there is an increase in mortality risk with a decrease in S/F_{94} on day 0 (Supplementary Figure 4b). Hence the reversed direction in the multivariable model is explained by the effect of change in S/F_{94} between day 0 and day 5, suggesting that patients who are admitted to hospital with moderate oxygenation defects, and deteriorate rapidly, have a slightly increased risk of mortality.



Supplementary Figure 4: Results of regression model for S/F_{94} , using mortality at day 28 as the outcome, in (a) multivariable model including both day 0 and day 5 S/F_{94} and (b) a univariate model with day 0 S/F_{94} as the sole predictor variable. The univariate model shows a clear and expected association between mortality at day 28 and S/F_{94} on day 0.



(a) S/F_{94} on Day 5 by WHO ordinal scale.



(d) S/F_{94} on Day 0

(e) S/F_{94} on Day 5

Supplementary Figure 5: Relationship between (a) Distribution of S/F_{94} values day 5 compared with WHO ordinal scale value at the same time point. For some patients who died on day 5, S/F_{94} values were available. For those with missing S/F_{94} values who died, an S/F_{94} of 0.5 was used to reflect poor pulmonary oxygenation function. (b) S/F_{94} on day 0 and 28-day outcome and (c) 28-day outcome and S/F_{94} on day 5 among selected patients meeting inclusion criteria (age 20-75; oxygen therapy in first 3 days) (d) 28-day outcome and S/F_{94} on day 0 and (e) 28-day outcome and S/F_{94} on day 5 among unselected patients. Hosp = hospitalised, no oxygen support; Ox = Hospitalised, oxygen by mask or nasal prongs; CPAP/HFNO = Hospitalised, oxygen by continuous positive airway pressure; high-flow nasal oxygen or noninvasive ventilation; IMV = Intubation and mechanical ventilation; IMV $S/F \leq 2$ = Mechanical ventilation; $S/F \leq 2$ or vasopressors; MOF = Multi-organ failure & mechanical ventilation & $S/F_{94} < 2$ & ECMO or renal replacement therapy.

1.2.3 Effect size estimation

This section details how effect sizes associated with a given treatment effect were calculated for different outcome measures.

1.2.3.1 S/F_{94} and sustained WHO ordinal scale improvement

We used a logistic model with mortality as the dependent variable, and separately estimated relationships with S/F_{94} and WHO ordinal scale improvement,

$$\ln\left(\frac{p_i}{1-p_i}\right) = \beta_0 + \beta_1 y_i + \beta \cdot z_i.$$
(1.1)

Here, p_i is the probability of day 28 mortality for individual i, β_0 and β_1 are scalar coefficients, β is an *n*-dimensional vector of coefficients, y_i is the outcome measure $(S/F_{94}$ or sustained WHO ordinal scale improvement encoded as a numeric variable taking values 0 or 1), and z_i is an *n*-dimensional vector of covariates.

Let $\hat{\beta}_0, \hat{\beta}_1, \hat{\beta}$ be consistent estimators for β_0, β_1, β respectively. \hat{p}_i is defined as the corresponding predicted probability of day 28 mortality for patient i,

$$\ln\left(\frac{\hat{p}_i}{1-\hat{p}_i}\right) = \hat{\beta}_0 + \hat{\beta}_1 y_i + \hat{\beta} \cdot z_i.$$
(1.2)

We consider an individual-specific treatment effect given by

$$p_i \to f(p_i) \tag{1.3}$$

for some function f taking values in [0, 1], that may in principle depend on all covariates. The changes Δ_i , $\hat{\Delta}_i$ in the outcome measure associated with this treatment effect for individual *i* keeping all other covariates constant in 1.1 and 1.2 satisfy

$$\ln\left(\frac{f(p_i)}{1-f(p_i)}\right) = \beta_0 + \beta_1(y_i + \Delta_i) + \beta \cdot z_i.$$
(1.4)

$$\ln\left(\frac{f(\hat{p}_i)}{1-f(\hat{p}_i)}\right) = \hat{\beta}_0 + \hat{\beta}_1(y_i + \hat{\Delta}_i) + \hat{\beta} \cdot z_i.$$

$$(1.5)$$

Our estimator for the expected change in y_i associated with the treatment effect f is obtained by subtracting 1.2 from 1.5, dividing by $\hat{\beta}_1$ and averaging over the sample,

$$\hat{\mu}_{\Delta} := \frac{1}{\hat{\beta}_1 I} \sum_{i=1}^{I} \ln \left(\frac{f(\hat{p}_i)(1-\hat{p}_i)}{\hat{p}_i(1-f(\hat{p}_i))} \right).$$
(1.6)

This is a consistent estimator for $\mu_{\Delta} = \mathbb{E}[\Delta_i]$, which follows from the fact that $\hat{\beta}_0, \hat{\beta}_1, \hat{\beta}$ are consistent estimators for β_0, β_1, β and assuming $\{\Delta_i\}_{i=1}^I$ is mean ergodic.

In the results presented in this paper, a treatment effect that is a relative risk reduction of e.g. 15% means that f is defined by

$$f(x) = 0.85x. (1.7)$$

That is, the patient's predicted risk of mortality is multiplied by 0.85.

1.2.3.2**Protocolised** S/F_{94}

In the ISARIC dataset, S/F_{94} measurements are made opportunistically. We expect protocolised S/F_{94} measurements to be more precise and to be a better predictor of mortality. This in turn implies that smaller sample sizes will be required when using protocolised S/F_{94} measurements as an intermediate endpoint in clinical trials.

In order to calculate the magnitude of this effect, we assume a measurement error model of the following form

$$y_i = \alpha_0 + \alpha_1 x_i + \epsilon_i, \tag{1.8}$$

where x_i is a protocolised measurement of S/F_{94} , α_0, α_1 are scalar coefficients, and ϵ_i is a residual.

We will use the notation

$$\mu_x := \mathbb{E}[x_i] \tag{1.9}$$

$$\mu_y := \mathbb{E}[y_i] \tag{1.10}$$

$$\sigma_x^2 := \operatorname{Var}[x_i] \tag{1.11}$$

$$\sigma_x^- := \operatorname{Var}[x_i] \tag{1.11}$$

$$\tau_y^2 := \operatorname{Var}[y_i]. \tag{1.12}$$

We also assume the moment conditions

$$\mathbb{E}[\epsilon_i] = 0 \tag{1.13}$$

$$\mathbb{E}[\epsilon_i x_i] = 0. \tag{1.14}$$

Combining 1.13 and 1.14 with 1.8 gives

$$\alpha_0 = \mu_y - \frac{\rho_{xy} \sigma_y \mu_x}{\sigma_x} \tag{1.15}$$

$$\alpha_1 = \frac{\rho_{xy}\sigma_y}{\sigma_x},\tag{1.16}$$

where ρ_{xy} is the Pearson correlation between x_i and y_i . Assuming $\{y_i\}_{i=1...I}$ is mean and variance ergodic, we have the following consistent estimators for μ_y and σ_y^2

$$\hat{\mu}_y := \frac{1}{I} \sum_{i=1}^{I} y_i \tag{1.17}$$

$$\hat{\sigma}_y^2 := \frac{1}{I} \sum_{i=1}^{I} (y_i - \hat{\mu}_y)^2 \tag{1.18}$$

Combining 1.1 with 1.8 gives

$$\ln\left(\frac{p_i}{1-p_i}\right) = \beta_0' + \beta_1' x_i + \beta_1 \epsilon_i + \beta \cdot z_i, \qquad (1.19)$$

where $\beta'_0 := \beta_0 + \alpha_0 \beta_1$ and $\beta'_1 = \alpha_1 \beta_1$.

Given knowledge of μ_x , σ_x and ρ_{xy} , α_0 and α_1 can be consistently estimated by substituting 1.17, 1.18 into 1.15 and 1.16. Denoting these estimators $\hat{\alpha}_0$ and $\hat{\alpha}_1$ respectively, we define

$$\ln\left(\frac{\hat{p}_i}{1-\hat{p}_i}\right) := \hat{\beta}_0' + \hat{\beta}_1' x_i + \hat{\beta} \cdot z_i, \qquad (1.20)$$

where $\hat{\beta}'_0 := \hat{\beta}_0 + \hat{\alpha}_0 \hat{\beta}_1$, $\hat{\beta}'_1 = \hat{\alpha}_1 \hat{\beta}_1$, and \hat{p}_i is the corresponding estimate of the probability of day 28 mortality for individual i. We have

$$\hat{\beta}_0' \xrightarrow{p} \beta_0' \tag{1.21}$$

$$\begin{array}{ccc} \beta_0 \to \beta_0 & (1.21) \\ \hat{\beta}'_1 \xrightarrow{p} \beta'_1, & (1.22) \end{array}$$

where \xrightarrow{p} denotes convergence in probability. If in addition we assume $\{\epsilon_i\}_{i=1}^I$ is mean ergodic, then using 1.13 gives

$$\operatorname{plim}_{I \to \infty} \frac{1}{I} \sum_{i=1}^{I} \left[\ln \left(\frac{p_i}{1 - p_i} \right) - \ln \left(\frac{\hat{p}_i}{1 - \hat{p}_i} \right) \right] = 0.$$
(1.23)

Now consider an individual-specific treatment effect given by

$$p_i \to f(p_i) \tag{1.24}$$

for some function f taking values in [0, 1], that may in principle depend on all covariates. Let $\Delta_i, \hat{\Delta}_i$ be the change in x_i associated with this treatment effect in 1.19 and 1.20 respectively. That is,

$$\ln\left(\frac{f(p_i)}{1-f(p_i)}\right) = \beta'_0 + \beta'_1(x_i + \Delta_i) + \beta_1\epsilon_i + \beta \cdot z_i.$$
(1.25)

$$\ln\left(\frac{f(\hat{p}_i)}{1-f(\hat{p}_i)}\right) = \hat{\beta}'_0 + \hat{\beta}'_1(x_i + \hat{\Delta}_i) + \hat{\beta} \cdot z_i.$$
(1.26)

Our estimator for the average change in protocolised S/F_{94} associated with the treatment effect f is obtained by subtracting 1.20 from 1.26, dividing by $\hat{\beta}'_1$ and averaging over the sample,

$$\hat{\mu}_{\Delta} = \frac{1}{\hat{\beta}_1' I} \sum_{i=1}^{I} \ln \left(\frac{f(\hat{p}_i)(1-\hat{p}_i)}{\hat{p}_i(1-f(\hat{p}_i))} \right).$$
(1.27)

We now show this is a consistent estimator for $\mu_{\Delta} := \mathbb{E}[\Delta_i]$ at first order in ϵ_i .

Consider

$$\hat{\mu}_{\Delta} - \frac{1}{I} \sum_{i=1}^{I} \Delta_{i} = \frac{1}{I} \sum_{i=1}^{I} \left(\frac{1}{\hat{\beta}_{1}'} \left[\ln \left(\frac{f(\hat{p}_{i})}{1 - f(\hat{p}_{i})} \right) - \ln \left(\frac{\hat{p}_{i}}{1 - \hat{p}_{i}} \right) \right] - \frac{1}{\beta_{1}'} \left[\ln \left(\frac{f(p_{i})}{1 - f(p_{i})} \right) + \ln \left(\frac{p_{i}}{1 - p_{i}} \right) \right] \right)$$
(1.28)

We assume f is analytic, and Taylor expand the third term in 1.28 to first order around $\epsilon_i = 0$. Let $g(\epsilon_i) = \ln \left[\frac{f(p_i)}{1 - f(p_i)} \right]$, where p_i is understood to be a function of ϵ_i via 1.19. Then

$$\hat{\mu}_{\Delta} - \frac{1}{I} \sum_{i=1}^{I} \Delta_i \simeq \frac{1}{I} \sum_{i=1}^{I} \left(\frac{1}{\hat{\beta}'_1} \left[\ln \left(\frac{f(\hat{p}_i)}{1 - f(\hat{p}_i)} \right) - \ln \left(\frac{\hat{p}_i}{1 - \hat{p}_i} \right) \right] - \frac{1}{\beta'_1} \left[g(\epsilon_i = 0) + g'(\epsilon_i = 0)\epsilon_i + \ln \left(\frac{p_i}{1 - p_i} \right) \right] \right)$$
(1.29)

Now taking probability limits and using 1.22, 1.23, as well as

$$\operatorname{plim}_{I \to \infty} \left(g(\epsilon_i = 0) - \ln \left(\frac{f(\hat{p}_i)}{1 - f(\hat{p}_i)} \right) \right) = 0 \tag{1.30}$$

$$\operatorname{plim}_{I \to \infty} \sum_{i=1}^{I} \epsilon_i = 0, \qquad (1.31)$$

we obtain

$$\operatorname{plim}_{I \to \infty} \left(\hat{\mu}_{\Delta} - \mu_{\Delta} \right) = 0, \tag{1.32}$$

where we have assumed $\{\Delta_i\}_{i=1}^I$ is mean ergodic. This is the desired consistency result.

Note that the form of the measurement error model 1.8 places some restriction on feasible values for ρ_{xy} . If we denote opportunistic and protocolised measurements on day d by y_d, x_d respectively, then using 1.8 and assuming σ_x, σ_y are constant over time we obtain

$$Cov(y_0, y_5) = \alpha_1^2 Cov(x_0, x_5).$$
(1.33)

Substituting in (5.16) gives

$$\operatorname{Corr}(y_0, y_5) = \rho_{xy}^2 \operatorname{Corr}(x_0, x_5),$$
 (1.34)

where Corr(.,.) denotes the pearson correlation. Since the pearson correlation takes values in [0, 1], we have

$$\operatorname{Corr}(y_0, y_5) \in [0, \rho_{xy}^2].$$
 (1.35)

We calculated effect sizes with protocolised S/F_{94} as outcome measure, with the means of the opportunistic and protocolised measurements set equal, and the standard deviation of protocolised S/F_{94} measurements set to 80% of the standard deviation of opportunistic SF/94 measurements. In the ISARIC4C data, the sample correlation between opportunistic S/F_{94} measurements on day 0 and day 5 was $\simeq 0.40$. Using 1.36 gives the constraint

$$\rho_{xy} \ge 0.63. \tag{1.36}$$

1.2.3.3 WHO ordinal scale

We used a proportional odds model to estimate the relationship between day 28 WHO ordinal scale category and individual characteristics,

$$\ln\left(\frac{p_{ij}}{1-p_{ij}}\right) = \beta_{0j} + \beta \cdot z_i. \tag{1.37}$$

Here, p_{ij} is the probability that the WHO ordinal scale category of individual *i* at day 28 is $\leq j$, β_{0j} are a set of constant terms for each WHO ordinal scale category, β is an *n*-dimensional vector of coefficients, and z_i is an *n*-dimensional vector of covariates.

j = 10 is the highest WHO ordinal scale category and corresponds to death. Then $q_{i10} := 1 - p_{i10}$ is the probability of day 28 mortality for patient *i*. We consider an individual-specific treatment effect given by

$$q_{i10} \to f(q_{i10}) \tag{1.38}$$

for some function f taking values in [0, 1], that may in principle depend on all covariates.

Let \hat{q}_{i10} denote the predicted probability of day 28 mortality for individual *i* derived from the model 1.37. Then the rate of predicted day 28 mortality in the sample can be estimated by $\bar{q}_{10} := \frac{1}{I} \sum_{i=1}^{I} \hat{q}_{i10}$. The odds ratio associated with the treatment effect *f* is estimated by

$$\frac{\left(\frac{f(\bar{q}_{10})}{1-f(\bar{q}_{10})}\right)}{\left(\frac{\bar{q}_{10}}{1-\bar{q}_{10}}\right)} = \frac{f(\bar{q}_{10})\left(1-\bar{q}_{10}\right)}{\bar{q}_{10}\left[1-f(\bar{q}_{10})\right]}.$$
(1.39)

We take this as our estimate of effect size.

1.2.4 Generation of synthetic data

A synthetic dataset was generated for use in the online sample size calculation tool. This dataset was achieved using imputation by chained equations in multiple stages. First, empty records for one thousand new patients at day zero were added to the real data. Next, variables that can be reasonably expected to be constant over a 28 day time period (e.g. comorbidities such as obesity, dementia, liver disease etc) were imputed by chained equations. New rows were added for day 5 and day 8 for each simulated record, with the constant variables imputed in the previous step repeated. After this, there were multiple rounds of partitioning the full dataset, containing both real and simulated records, and carrying out imputation by chained equations separately within each piece. For example, a binary variable indicating whether an individual died was imputed, then the full dataset was split into those who died and those who didn't, and a day of death was imputed for the former. Similarly, binary variables indicating whether or not the individual had a one/two level sustained improvement in WHO ordinal severity score were imputed, and used to partition the full dataset. Then the minimum time taken for patients to have a sustained one/two level improvement was imputed amongst those that had this event occur. Appropriate care was taken in order to respect variable bounds, interdependence and the time series structure of the data. For example, if an individual had a sustained two level improvement, they necessarily must also have had a sustained one level improvement, and the time taken for the former to occur must necessarily be greater than or equal to the time taken for the latter to occur. In order to handle this appropriately, we first imputed the time taken for a sustained one level improvement, and after appropriate partitioning, we then imputed the

difference in time taken for a sustained one and two level improvement using predictive mean matching. This guaranteed a positive difference, as required.

In each imputation by chained equations, predictive mean matching was used for continuous variables and logistic or multinomial logistic regression was used for categorical variables.

1.3 Inclusion criteria

We compared the effect on sample size using different inclusion criteria (Supplementary Tables 2, 3 and 4). In general, as expected, the more broad the inclusion criteria (e.g. only age limits), the larger the sample size that is needed; and the more specific the inclusion criteria, the smaller the sample size. However it is important to note that using very specific inclusion criteria increases the burden associated with screening patients for inclusion in a study, which may substantially decrease real-world recruitment.

Selection criteria	$S_a O_2 < 0.94$ or $F_I O_2 = 0.21$	$S_a O_2 > 0.94$	Day 0 and $(S_a O_2 < 0.94)$ or $F_I O_2 = 0.21$	Day 0 and $S_a O_2 > 0.94$	
Number of entries	192,583 100,040	55,765	114,668	27,367	
Umque subjects	129,049 71 / 77 99)	39,457 60 (FF 90)	114,088	21,367	
Age, years	(1 (57-82) (1 (57-82)	09 (55-82)	72 (58-83)	70 (55-82)	
Male	111,244 $(58%)$	32,022 $(58%)$	$63,127\ (55\%)$	$15,351\ (56\%)$	
Respiratory rate, per minute	20(18-25)	22(18-26)	20(18-25)	22(18-25)	
Temperature, Celsius	37.2(36.8-38.0)	37.1(36.7-37.8)	37.3 (36.8-38.1)	$37.3 \ (36.8 - 38.1)$	
Systolic blood pressure, mmHg	116(103-138)	$120\ (105\text{-}140)$	117 (104 - 138)	121(106-142)	
Diastolic blood pressure, mmHg	66 (57-77)	69(59-77)	68 (58-79)	70(60-81)	
CRP, mg/L	85(39-159)	84(39-152)	78(34-145)	84(40-149)	
BUN, $mmol/L$	7.0(4.8-10.9)	$6.7 \ (4.6-10.5)$	$6.7 \ (4.6-10.3)$	6.5(4.5-10.1)	
Creatinine, umol/L	86(68-120)	84(67-119)	88 (70-119)	86(70-116)	
Urine production, $ml/24h$	$1,001 \ (400-1839)$	1,020 (450-1890)	500(300-950)	$550\ (300\text{-}1,000)$	
Glasgow Coma Scale	15(15-15)	15 (15-15)	15(15-15)	15(15-15)	
Clinical frailty	4(2-6)	4(2-6)	4(3-6)	4(2-6)	
Onset to admission, days	4(0-8)	4 (0-8)	3(0-7)	4(0-8)	
Infiltrates on X-ray present	$52,001\ (67\%)$	$14,525\ (69\%)$	41,944~(63%)	$12,147\;(67\%)$	
No respiratory support (WHO 4)	71,633 $(37%)$	(%0) (0%)	$11,187\ (23\%)$	$0\ (0\%)$	
Nasal oxygen (WHO 5)	53,610~(28%)	23,220 $(42%)$	$19,904\ (41\%)$	$10,102\;(64\%)$	
Non invasive ventilation (WHO 6)	46,473 $(24%)$	$11,764\ (21\%)$	$15,370\ (32\%)$	5,148~(32%)	
IMV: SF $>$ 2.0 (WHO 7)	3,063~(2%)	$1,789\ (3\%)$	249~(<1%)	$172\ (1\%)$	
IMV: $SF < 2.0$ or	8,782 $(5%)$	$1,900\ (3\%)$	1,174~(2%)	345~(2%)	
vasopressor (WHO 8)					
IMV: SF<2.0 and	3,004~(2%)	$784\ (1\%)$	401~(<1%)	$151\ (1\%)$	
vasopressor, ECMO or					
dialysis (WHO 9)					
Death (WHO 10)	30,225 ($23%$)	8,289(21%)	26,017 (23%)	5,924 (22%)	
Discritation and e functioning transfer to other facility)	90,024 (11 /0)	07,100 (1970)	(0/11) 160,000	21,4 1 0 (10/0)	

Supplementary Table 1: Characteristics of patient populations meeting criteria for S/F 94 measurement in ISARIC4C data. Continuous values are summarised as median (inter quartile range). Categorical values are summarised as frequency (percentage). Subjects meeting the criteria for S/F 94 $(S_aO_2 < 0.94 \text{ or } F_IO_2 = 0.21)$ were compared to patients not meeting the S/F 94 criteria. Comparison was done both for all entries during admission and day 0. CRP = C-reactive protein, BUN = blood urea nitrogen

Maaa	Distribution/	Estimated treatment	Total n required
Measure	Event rate	effect	80% power $2p = 0.05$
S/F_{94} day 5	$Mean = 2.40 \ SD = 1.32 \ ho ext{ vs Day 0: } 0.43$	Difference in S/F_{94} : 0.175	1,454
S/F_{94} day 8	$egin{array}{l} { m Mean}=2.74\ { m SD}=1.54\ ho\ { m vs}\ { m Day}\ 0:\ 0.40 \end{array}$	Difference in S/F_{94} : 0.154	2,636
WHO day 5	$\begin{array}{r} 4:\ 1,502/8,315\\ 5:\ 1,861/8,315\\ 6:\ 2,270/8,315\\ 7:\ 301/8,315\\ 8:\ 980/8,315\\ 9:\ 313/8,315\\ 10:\ 1,088/8,315\end{array}$	Proportional odds ratio: 0.83	2,881
WHO day 8	$\begin{array}{c} 4:\ 1,436/6,942\\ 5:\ 1,206/6,942\\ 6:\ 1,196/6,942\\ 7:\ 361/6,942\\ 8:\ 812/6,942\\ 9:\ 261/6,942\\ 10:\ 1,670/6,942\end{array}$	Proportional odds ratio: 0.81	2,234
1-level sustained improvement	12,057/26,854 (44.9%)	Risk ratio: 1.03	6,544
2-level sustained improvement	4,914/26,854 (18.3%)	Risk ratio: 1.04	3,722
28-day mortality	7,583/36,559~(20.7%)	Risk ratio: 0.85	5,154

Supplementary Table 2: Comparison of outcome measures among 36,559 hospitalised patients aged 20-75, who required supplemental oxygen on the day of admission. The estimated treatment effect is for a 15% relative reduction in mortality. For S/F_{94} , the mean value and standard deviation (SD) and the correlation with S/F_{94} on day 0 are reported for both day 5 and day 8. For the WHO ordinal severity scale, the number of people in each group between 4 (hospitalised, no oxygen support) and 10 (dead) are reported. For 1- and 2-level sustained improvement, the number of people reaching sustained improvement is reported. For 28-day mortality, the proportion of patients who died at day 28 is reported. Sample sizes shows the total number of subjects needed in both arms using a 1:1 allocation.

Maaguma	Distribution/	Estimated treatment	Total n required
Measure	Event rate	effect	80% power $2p = 0.05$
S/F_{94} day 5	$egin{array}{llllllllllllllllllllllllllllllllllll$	Difference in S/F_{94} : 0.172	1,566
S/F_{94} day 8	$egin{array}{llllllllllllllllllllllllllllllllllll$	Difference in S/F_{94} : 0.151	2,650
WHO day 5	$\begin{array}{l} 4:\ 3,162/14,082\\ 5:\ 2,903/14,082\\ 6:\ 3,091/14,082\\ 7:\ 385/14,082\\ 8:\ 1,198/14,082\\ 9:\ 438/14,082\\ 10:\ 2,905/14,082\end{array}$	Proportional odds ratio: 0.82	2,431
WHO day 8	$\begin{array}{r} 4:\ 2,708/11,953\\ 5:\ 1,880/11,953\\ 6:\ 1,688/11,953\\ 7:\ 455/11,953\\ 8:\ 1,037/11,953\\ 9:\ 370/11,953\\ 10:\ 3,815/11,953\end{array}$	Proportional odds ratio: 0.79	1,855
1-level sustained improvement	14,556/47,260 (30.8%)	Risk ratio: 1.03	6,061
2-level sustained improvement	5,860/47,260~(12.4%)	Risk ratio: 1.04	2,959
28-day mortality	10,811/69,464~(15.6%)	Risk ratio: 0.85	7,267

Supplementary Table 3: Comparison of outcome measures among 69,464 hospitalised patients aged 20-75. The estimated treatment effect is for a 15% relative reduction in mortality. For S/F_{94} , the mean value and standard deviation (SD) and the correlation with S/F_{94} on day 0 are reported for both day 5 and day 8. For the WHO ordinal severity scale, the number of people in each group between 4 (hospitalised, no oxygen support) and 10 (dead) are reported. For 1- and 2-level sustained improvement, the number of people reaching sustained improvement is reported. For 28-day mortality, the proportion of patients who died at day 28 is reported. Sample sizes shows the total number of subjects needed in both arms using a 1:1 allocation.

Measure	Distribution/ Event rate	Estimated treatment effect	Total n required 80% power $2p = 0.05$
S/F_{94} day 5	$\begin{array}{l} {\rm Mean} = 2.40 \\ {\rm SD} = 1.29 \\ \rho \ {\rm vs \ Day \ 0: \ 0.32} \end{array}$	Difference in S/F_{94} : 0.180	1,462
S/F_{94} day 8	$egin{array}{llllllllllllllllllllllllllllllllllll$	Difference in S/F_{94} : 0.158	2,644
WHO day 5	$\begin{array}{l} 4: \ 1,770/10,039\\ 5: \ 2,433/10,039\\ 6: \ 2,736/10,039\\ 7: \ 363/10,039\\ 8: \ 1,145/10,039\\ 9: \ 418/10,039\\ 10: \ 1,174/10,039\end{array}$	Proportional odds ratio: 0.83	2,971
WHO day 8	$\begin{array}{l} 4: \ 1,685/8,240\\ 5: \ 1,525/8,240\\ 6: \ 1,445/8,240\\ 7: \ 429/8,240\\ 8: \ 968/8,240\\ 9: \ 343/8,240\\ 10: \ 1,844/8,240 \end{array}$	Proportional odds ratio: 0.81	2,321
1-level sustained improvement	13,437/30,060 (44.7%)	Risk ratio: 1.03	6,756
2-level sustained improvement	5,411/30,060~(18.0%)	Risk ratio: 1.04	3,808
28-day mortality	8,262/39,765~(20.8%)	Risk ratio: 0.85	$5,\!143$

Supplementary Table 4: Comparison of outcome measures among 39,765 hospitalised patients aged 20-75, who required supplemental oxygen in the first 3 days in hospital. The estimated treatment effect is for a 15% relative reduction in mortality